COLAR: open-label clinical study of IL-6 blockade with tocilizumab for the treatment of immune checkpoint inhibitor-induced colitis and arthritis

医学 托珠单抗 易普利姆玛 内科学 临床终点 不利影响 胃肠病学 结肠炎 不良事件通用术语标准 无容量 癌症 类风湿性关节炎 临床试验 免疫疗法
作者
Rikke Boedker Holmstroem,Ole Haagen Nielsen,Søren Jacobsen,Lene Buhl Riis,Susann Theile,Jacob Tveiten Bjerrum,Peter Vilmann,Julia Sidenius Johansen,Mogens Karsbøl Boisen,Rikke Løvendahl Eefsen,Inge Marie Svane,Dorte Lisbet Nielsen,Inna Markovna Chen
出处
期刊:Journal for ImmunoTherapy of Cancer [BMJ]
卷期号:10 (9): e005111-e005111 被引量:98
标识
DOI:10.1136/jitc-2022-005111
摘要

BACKGROUND: Immune-related adverse events due to immune checkpoint inhibitors (ICIs) are not always effectively treated using glucocorticoids and it may negatively affect the antitumor efficacy of ICIs. Interventional studies of alternatives to glucocorticoids are lacking. We examined whether interleukin-6 blockade by tocilizumab reduced ICI-induced colitis and arthritis. PATIENTS AND METHODS: Patients with solid cancer experiencing Common Terminology Criteria for Adverse Events (CTCAE v5.0) grade >1 ICI-induced colitis/diarrhea (n=9), arthritis (n=9), or both (n=2) were recruited and treated with tocilizumab (8 mg/kg) every 4 weeks until worsening or unacceptable toxicity. Patients were not allowed to receive systemic glucocorticoids and other immunosuppressive drugs within the 14-day screening period. The primary endpoint was clinical improvement of colitis and arthritis, defined as ≥1 grade CTCAE reduction within 8 weeks. Secondary endpoints were improvements and glucocorticoid-free remission at week 24; safety; radiologic, endoscopic, and histological changes; and changes in plasma concentrations of C reactive protein, cytokines (IL-6, IL-8, and IL-17), and YKL-40. RESULTS: Nineteen patients were available for efficacy analysis; one patient was excluded due to pancreatic insufficiency-induced diarrhea. Patients received treatment with pembrolizumab (n=10) or nivolumab (n=4) as monotherapy or ipilimumab and nivolumab (n=5) combined. Seven patients had been initially treated with glucocorticoids, and two of them also received infliximab. Ten patients continued ICI therapy during tocilizumab treatment. The primary endpoint was achieved in 15 of 19 (79%) patients. Additional one patient had ≥1 grade reduction at week 10, and another patient had stabilized symptoms. At week 24, ongoing improvement without glucocorticoids (n=12), including complete remission (n=10), was noted. Five patients had grades 3-4 treatment-related adverse events, which were manageable and reversible. CONCLUSIONS: Tocilizumab showed promising clinical efficacy and a manageable safety profile in the treatment of ICI-induced colitis and arthritis. Our findings support the feasibility of randomized trials of immune-related adverse events. TRIAL REGISTRATION NUMBER: NCT03601611.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
欢呼馒头完成签到 ,获得积分10
刚刚
斯文败类的应助被u雨采纳,获得10
4秒前
正直从凝完成签到 ,获得积分10
4秒前
研友_VZG7GZ的应助被季末默相依采纳,获得10
5秒前
自觉大门完成签到,获得积分10
11秒前
Jackcaosky完成签到 ,获得积分10
11秒前
11qkk完成签到 ,获得积分10
11秒前
斯文败类的应助被wangji_2017采纳,获得10
12秒前
慕容博完成签到 ,获得积分10
13秒前
鼠牵牛完成签到,获得积分10
13秒前
Chen14完成签到 ,获得积分10
15秒前
优雅的水桃完成签到 ,获得积分10
16秒前
萌新完成签到,获得积分10
17秒前
ZZzz完成签到 ,获得积分10
17秒前
Orange的应助被tszjw168采纳,获得10
18秒前
bobo完成签到,获得积分10
27秒前
轻嚣完成签到 ,获得积分10
32秒前
欢喜的如凡完成签到 ,获得积分10
32秒前
000001完成签到,获得积分10
35秒前
35秒前
lyra1111完成签到,获得积分10
36秒前
37秒前
爱我不上火完成签到 ,获得积分10
37秒前
JAYEN完成签到 ,获得积分10
37秒前
Lxx完成签到 ,获得积分10
38秒前
40秒前
简爱完成签到 ,获得积分10
40秒前
LEO2025完成签到 ,获得积分10
41秒前
tszjw168发布了新的文献求助10
41秒前
大方的仙人掌完成签到,获得积分10
41秒前
L050完成签到 ,获得积分10
44秒前
Charlie完成签到 ,获得积分10
44秒前
幸福妙柏完成签到 ,获得积分10
45秒前
宁静的夏天的应助被学不可以已采纳,获得500
48秒前
Chaowei_L完成签到,获得积分10
49秒前
海布里的风完成签到 ,获得积分10
52秒前
王大发完成签到,获得积分10
52秒前
沉默的元枫完成签到,获得积分10
55秒前
tt完成签到,获得积分10
55秒前
乐观的自行车完成签到 ,获得积分10
56秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180084
求助须知:如何正确求助?哪些是违规求助? 9570224
关于积分的说明 21808758
捐赠科研通 7776098
什么是DOI,文献DOI怎么找? 3433261
关于科研通互助平台的介绍 2557454
邀请新用户注册赠送积分活动 2479012